CCDC22

Across TCGA pan-cancer cohorts, CCDC22 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CCDC22 data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CCDC22 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CCDC22 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, LUAD, and UCEC are the cancer types where CCDC22 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	0.949	0.719	.007	34	view →
LUAD	DFS	Median	II,III,IV	0.692	0.965	.004	17	view →
UCEC	OS	Median	II,III,IV	0.596	0.937	.033	8	view →
PDAC	DFS	Quartile	All	0.484	0.332	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CCDC22–CCRCC (OS)

Open the CCRCC breakdown →